Vera Therapeutics Inc [NASDAQ: VERA] slipped around -3.52 points on Tuesday, while shares priced at $22.01 at the close of the session, down -13.79%.
Compared to the average trading volume of 1.02M shares, VERA reached a trading volume of 4142813 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about Vera Therapeutics Inc [VERA]?
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for VERA shares is $65.00 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on VERA stock is a recommendation set at 1.14. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
H.C. Wainwright have made an estimate for Vera Therapeutics Inc shares, keeping their opinion on the stock as Buy, with their previous recommendation back on May 05, 2025. While these analysts kept the previous recommendation, Wolfe Research raised their target price to Outperform. The new note on the price target was released on February 04, 2025, representing the official price target for Vera Therapeutics Inc stock. Previously, the target price had yet another raise to $58, while Goldman analysts kept a Buy rating on VERA stock.
The Average True Range (ATR) for Vera Therapeutics Inc is set at 1.68 The Price to Book ratio for the last quarter was 2.42, with the Price to Cash per share for the same quarter was set at 10.05.
How has VERA stock performed recently?
Vera Therapeutics Inc [VERA] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -8.29. With this latest performance, VERA shares gained by 3.28% in over the last four-week period, additionally sinking by -45.49% over the last 6 months – not to mention a drop of -49.40% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for VERA stock in for the last two-week period is set at 42.80, with the RSI for the last a single of trading hit 41.53, and the three-weeks RSI is set at 42.18 for Vera Therapeutics Inc [VERA]. The present Moving Average for the last 50 days of trading for this stock 25.07, while it was recorded at 23.99 for the last single week of trading, and 36.41 for the last 200 days.
Vera Therapeutics Inc [VERA]: Deeper insight into the fundamentals
Vera Therapeutics Inc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 25.58 and a Current Ratio set at 25.58.
Earnings analysis for Vera Therapeutics Inc [VERA]
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for VERA. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Vera Therapeutics Inc go to 13.41%.
Insider trade positions for Vera Therapeutics Inc [VERA]
The top three institutional holders of VERA stocks are: AVORO CAPITAL ADVISORS LLC with ownership of 4.31 million shares, which is approximately 7.8745%. PRICE T ROWE ASSOCIATES INC /MD/, holding 3.62 million shares of the stock with an approximate value of $$130.98 million in VERA stocks shares; and PRICE T ROWE ASSOCIATES INC /MD/, currently with $$120.76 million in VERA stock with ownership which is approximately 6.0986%.
